Metalloenzyme Inhibitors for Treating Cancers, Alzheimer's Disease, Hemochromatosis, and Other Disorders
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/US2021/055327, filed Oct 16, 2021. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,780,802 | Metalloenzyme Inhibitors for Treating Cancers, Alzheimer's Disease, Hemochromatosis, and Other Disorders In force · High confidence | Miralogx LLC | In force | High confidence | ||
| US 12,358,892 | Metalloenzyme Inhibitors for Treating Cancers, Alzheimer's Disease, Hemochromatosis, and Other Disorders In force · High confidence | Miralogx LLC | In force | High confidence |
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.